Psilocybin Cuts Lyme Symptoms 40%, FDA Clears PTSD Trial, and Mushrooms Target Breast Cancer

Hi Shroomers. Mushrooms continue to surprise me in how many different parts of life they touch. This week alone, they show up in everything from potential breast cancer targets to childhood development and even renewable energy systems.

There’s also a wave of new psilocybin research moving forward, including an FDA-cleared PTSD trial and early results suggesting meaningful relief for people living with chronic Lyme disease.

And on the cultivation side, researchers are discovering that something as simple as adjusting LED light spectra can change how cordyceps grows and how much of its key medicinal compounds it produces.

Breast cancer target 🎗️ Compounds in turkey tail (Trametes versicolor) and enoki (Flammulina velutipes) may help interfere with HER2, a protein that drives 15–20% of aggressive breast cancers. Enoki reduced inflammatory protein damage with strong activity at 2.86 µg/mL, while turkey tail blocked 62.5% of inflammation-related protein breakdown at 500 µg/mL. Natural compounds in the mushrooms bound tightly to the HER2 protein (−5.88 to −5.24 kcal/mol), similar to the chemotherapy drug doxorubicin (−5.43 kcal/mol).

Shiitake rash reaction 💓 Eating raw or undercooked shiitake mushrooms (Lentinula edodes) can trigger a distinctive whip-like skin rash that appears 24–72 hours after eating in sensitive people. The reaction is linked to lentinan, a mushroom polysaccharide that can trigger a hypersensitivity response and produce linear red lesions across the trunk and arms. The condition is rare with ~150 cases reported worldwide and the compound is neutralized when mushrooms are cooked above 293°F, which prevents the reaction.

Social development boost 👶 Children whose mothers ate mushrooms during pregnancy were less likely to develop peer-relationship problems and low prosocial behavior by age five. In a cohort of ~64,000 mother–child pairs, higher maternal mushroom intake was linked to about a 15–20% lower risk of peer problems and a ~10–15% lower risk of poor prosocial behavior compared with low intake. Mushrooms provide nutrients like ergothioneine and vitamin D, which may support early brain and behavioral development during pregnancy.

Faster wound repair 🩹 Puffball mushroom (Bovistella utriformis) polysaccharides helped skin cells grow and repair tissue without damaging healthy cells. Human skin cells kept over 68% viability across doses from 19.5 to 10,000 µg/mL, with cell growth rising to 130% and 126% viability at 5,000 and 10,000 µg/mL, showing strong regenerative activity. In wound-closure tests, the extract achieved 40% scratch closure within 32 hours at 500 µg/mL, supporting its potential for skin-healing applications.

Soup digestion shift 🍲 Button mushrooms (Agaricus bisporus) and other mushroom-rich vegan soups still delivered strong antioxidant and anti-inflammatory activity after simulated digestion. Antioxidant capacity reached about 14.5 µmol Trolox equivalents per g, while compounds that block acetylcholinesterase, an enzyme tied to memory decline, remained active after digestion. The results show that even after the digestive process, mushroom-based soups can retain measurable brain- and inflammation-supporting bioactivity.

Coma brain reboot 📈 Computer simulations suggest psychedelics like psilocybin and LSD could push damaged brains closer to a “critical” activity state linked to consciousness. In whole-brain models of patients with disorders of consciousness, the drugs increased network complexity and signal integration, patterns associated with more responsive and awake brain dynamics.

Microdose depression trial 🎈 This randomized clinical trial enrolled 39 adults with major depressive disorder (ages 27–65) and tested 2 mg psilocybin taken once per week. Participants were split into psilocybin-first (18 people) and placebo-first (17 people) groups for the first 4 weeks, followed by 4 weeks where everyone received psilocybin. Depression scores dropped in both groups over time, and the treatment was well tolerated with no serious adverse events, but the psilocybin group did not show significantly greater symptom reduction than placebo.

Lyme relief 🪲 People with chronic post-treatment Lyme disease often struggle with long-lasting fatigue, pain, brain fog, and depression, and this pilot trial found meaningful symptom improvements lasting up to 6 months after psilocybin therapy. In an 8-week open-label study of 20 participants, patients received two psilocybin sessions (15 mg followed by 15–25 mg) with psychological support. Overall Lyme symptom burden dropped 40% at 6 months, while quality-of-life scores improved 13%, with significant improvements also seen in mood, fatigue, sleep, and pain.

PTSD trial 💊 The FDA cleared a Phase 2b/3 clinical trial testing COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD). The 12-week study will give participants two sessions of 25 mg psilocybin (vs. 1 mg control) spaced about 4 weeks apart, measuring symptom change using the CAPS-5 PTSD severity scale at week 8, followed by a 40-week safety follow-up. Earlier Phase 2 data showed a ~30-point average reduction in CAPS-5 scores by week 4 after a single 25 mg dose, with no serious adverse events reported.

Therapist effect 📿 Who guides a psilocybin therapy session can significantly shape the experience for patients receiving psychedelic treatment. Across 298 participants and 670 psilocybin sessions with 60 facilitators, facilitator differences explained 13.6% of experience variation in clinical patients but only 0.8% in healthy volunteers. The effect size is larger than the typical ~8% therapist effect in conventional psychotherapy, showing that facilitator training and support can meaningfully influence psychedelic therapy outcomes.

Waste-to-energy boost ⚡ Fungi can help wastewater plants convert sludge into more renewable methane fuel. Adding a fungus-degrading microbial consortium increased methane production from waste-activated sludge by about 35% (from ~40 mL to ~54.5 mL of CH₄) during anaerobic digestion. The fungi broke down tough cell-wall materials like chitin, mannan, and glucans, releasing more organic matter for methane-producing microbes to convert into energy.

Self-activating mold defense 🦠 A new antifungal material stays inactive until mold begins growing, then releases natural antifungal compounds to stop contamination. The system uses plant essential oils linked to a polymer that only breaks down when fungi create acidic metabolites and moisture, triggering targeted antifungal release. This controlled response reduces volatility and extends protection, allowing long-term mold inhibition without continuous chemical exposure.

Oyster seasoning powder 🧂 Oyster mushroom (Pleurotus sajor-caju) can be processed into a shelf-stable plant-based seasoning powder while preserving flavor and nutritional compounds. Researchers found the most stable formulation used 10% maltodextrin and 1% gum arabic as drying carriers, producing a powder with low water activity (0.42) and moisture around 4–5%, conditions that help prevent microbial growth. The final seasoning retained key flavor compounds including 10.86 mg glutamic acid per 100 g along with measurable phenolics and flavonoids, showing mushrooms can function as a natural umami seasoning ingredient.

Mushroom meatloaf test 🧆 Button mushroom (Agaricus bisporus) combined with textured vegetable protein (TVP) can produce a plant-based meatloaf with strong nutrition and consumer appeal. The optimized formulation used 40% mushroom and 60% TVP, delivering about 19–21% protein while lowering fat compared with conventional meatloaf. Sensory testing with 30 panelists rated the product highly for texture, flavor, and overall acceptability, showing mushrooms can improve both taste and nutrition in plant-based meat alternatives.

Coconut waste substrate 🥥 Coconut agricultural waste can successfully grow edible mushrooms by supporting strong mycelial growth and fruiting body production. In cultivation trials, mushrooms grown on coconut-based substrates produced comparable yields and biological efficiency to conventional substrates, demonstrating that coconut husk and fiber residues can function as effective growth media. The findings suggest coconut waste could become a low-cost, sustainable substrate that recycles agricultural by-products while supporting commercial mushroom cultivation.

Light tuning 💡 Cordyceps mushroom (Cordyceps militaris) growth and medicinal compound production can be significantly altered by LED light spectra during cultivation. In trials testing 9 different LED combinations, red-white light (2R:3W) and warm white produced larger colonies and higher stromata biomass, while a red-blue-white mix (3R:2B:1W) generated the highest cordycepin levels, one of the mushroom’s key bioactive compounds. The results show that adjusting light spectra can directly shape mushroom size, structure, and medicinal compound output, offering a simple way to optimize commercial cordyceps production.